Biotech Industry Leader Elected to Institute Board.Business Editors & Health/Medical Writers BIOWIRE2K LA JOLLA La Jolla (lə hoi`yə), on the Pacific Ocean, S Calif., an uninc. district within the confines of San Diego; founded 1869. The beautiful ocean beaches, in particular La Jolla shores and Black's Beach, and sea-washed caves attract visitors and , Calif.--(BW HealthWire)--Oct. 18, 2001 Stephen Chang, Ph.D., chief scientific officer, Canji Inc., a San Diego-based subsidiary of Schering-Plough, was elected to the board of directors of California Healthcare Institute (CHI). CHI is a non-profit public policy research organization representing leading California academic institutions, biotechnology, medical device, and pharmaceutical firms. Canji is developing drugs based on genes that suppress the development and hyperproliferation of cells. Their potential products are focused on cancers, eye diseases, and wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by . Prior to joining Canji in 1998, Chang was the director of research for Chiron Technologies' Center for Gene Therapy in San Diego and Chiron Inc. for three years. From 1988 to 1995, Chang held successive research and managerial positions in viral and genetic therapeutics at Viagene Inc. in San Diego, before being appointed director of viral and genetic therapeutics and senior principal scientist in 1994. Chang holds a bachelor's degree in cell and molecular biology Cell and Molecular Biology may refer to:
"As a scientist and an entrepreneur, Stephen Chang exemplifies CHI's commitment to biomedical research and development," said David Gollaher, Ph.D., CHI president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. . "Genetic medicine raises a number of difficult public policy issues, and we are delighted that Dr. Chang is joining our coalition." CHI represents more than 200 leading biotechnology, medical device, diagnostics and pharmaceutical companies, and public and private academic biomedical research organizations. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI's Web site is http://www.chi.org. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion